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Autoimmune encephalitis (AE) mediated by antibodies against synaptic and neuronal 
surface targets frequently presents with a psychiatric syndrome. In these patients, 
removal of autoantibodies treats the disease and outcomes are closely linked to 
early intervention. The discovery of these autoantibodies in isolated psychiatric syn-
dromes has raised the possibility that these patients may derive similar benefits from 
immunotherapy, a potentially transformational approach to the treatment of mental 
illness. Although open-label case series suggest impressive therapeutic outcomes, 
the pathological relevance of these autoantibodies outside of canonical presentations 
is debated. The advent of diagnostic criteria for AE attempts to facilitate its prompt 
identification but risks prematurely neglecting the potential scientific and clinical signifi-
cance of isolated syndromes that do not satisfy these criteria. Here, we propose using 
a syndrome-level taxonomy that has occasional, but not necessary, overlap with AE: 
synaptic and neuronal autoantibody-associated psychiatric syndromes or “SNAps”. 
This will prevent confusion with AE and act heuristically to promote active investigation 
into this rare example of psychopathology defined on a molecular level. We suggest 
that this concept would have application in other autoantibody-associated syndromes 
including seizure, cognitive, and movement disorders, in which similar issues arise. 
We review putative direct and indirect mechanisms and outline experimentally testable 
hypotheses that would help to determine prospectively in whom autoantibody detection 
is relevant, and as important, in whom it is not. We summarize a pragmatic approach 
to autoantibody testing and management in severe mental illness in order to promptly 
diagnose AE and advocate a research-orientated experimental medicine paradigm for 
SNAps, where there is greater equipoise. We conclude that SNAps remains a nascent 
area of clinical neuroscience with great potential and in ongoing need of psychiatry-led 
basic and clinical research.
Keywords: autoimmune diseases of the nervous system, mild encephalitis, glutamatergic neurotransmission, 
blood–brain barrier disruption, immunotherapy, schizophrenia, bipolar disorder, major depression
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introdUCtion
The serum of patients with functional psychoses contains 
abnormal globulins … I have previously suggested that 
an autoimmune mechanism might be involved … any 
interpretation of their meaning is completely specula-
tive and must be approached with the greatest caution.
W. J. Fessel, Autoimmunity and Mental Illness,  
1962 (1).
Antibodies that bind to cell surface neuronal, glial, or synaptic 
targets, collectively known as neural surface antibodies (NSAbs), 
have attracted significant attention in neurology and psychiatry 
(2). Their detection in a patient presenting with psychiatric symp-
toms raises the possibility both of a causal or disease-modifying 
role and of clinical improvement with immunotherapy (IT). 
This would represent a major step forward from current largely 
symptom-targeted psychotropic medications and has been met 
by clinicians and researchers with enthusiasm.
Although this iteration of autoimmune psychiatry is in 
its infancy (3), here we argue that there already exists ample 
evidence to warrant an expanding research program, focusing 
on robustly establishing the prevalence and relevance of NSAbs 
in what would otherwise appear to be primary psychiatric 
disorders. We discuss the controversies in applying knowledge 
of autoimmune encephalitis (AE) to such psychiatric disorders 
and suggest experiments by which these controversies may be 
resolved.
are ae and psyCHiatriC syndroMes 
assoCiated WitH nsabs reLated?
Given the prominence of psychiatric symptoms in many types 
of AE, and the known importance of receptor targets of NSAbs 
to psychopathology in psychiatric disorders, there have been 
extensive efforts to define disease-relevant associations between 
NSAbs and isolated psychiatric syndromes such as first-episode 
psychosis (FEP) (4). The development of assays able to detect 
specific antibodies against central nervous system (CNS) neural 
surface antigens in combination with careful clinical phenotyp-
ing has made this possible. Primary psychiatric disorders, such 
as schizophrenia, are far more common than AE. If a proportion 
of these were to have an NSAb-related etiology, then applying the 
lessons from the rare disease could stand to benefit a far larger 
group of patients.
Differences in acuity of sample timing, serum testing without 
paired cerebrospinal fluid (CSF), and variations in assay method 
have led to a lack of consensus on prevalence of NSAbs in psy-
chiatric illness. Initially, higher rates of autoantibody prevalence 
were found early in psychotic illnesses compared to the chronic 
phase (5), but some evidence makes this distinction less clear (6). 
Live, non-permeabilized cell-based assays (CBAs) largely find 
higher NSAb prevalence in patients compared to controls (7, 8), 
but this has not been wholly true of fixed permeabilized CBAs 
(9–11). The use of CBAs in isolation has been criticized for lack-
ing disease relevance (12); however, some studies supplementing 
CBA with immunohistochemistry and/or neuronal staining do 
in fact detect differences between cases and controls in certain 
psychiatric syndromes such as postpartum psychosis (13).
The rapid development of knowledge on AE, and the increas-
ing and potentially confusing “phenotype spread” associated 
with NSAbs, have inspired diagnostic criteria for AE (14). 
These focus on early detection prompting timely IT. Diagnosis 
is deemed more likely with multiple symptoms, symptoms 
spanning both neurological and psychiatric domains, and 
supportive imaging, electroencephalogram (EEG), and CSF 
changes. Less emphasis is placed on NSAb detection as AEs 
tend to present stereotypically and can be recognized with 
readily available investigations, whereas NSAb results may 
take several weeks to process. However, by definition, psychi-
atric syndromes with serum NSAb positivity on routinely used 
CBAs will be incompatible with this system. To illustrate, for 
NMDAR antibody positivity to be relevant by these criteria, it 
either needs to be detected in CSF or in serum with multiple 
assay methods, and “relevance” equates only to a diagnosis of 
NMDAR-AE. Given that NMDAR antibodies are the most com-
monly detected NSAb in isolated psychiatric syndromes (9), 
and that NMDAR-AE occasionally does not progress beyond 
psychosis, this has implications for much of the field. NSAbs 
found in isolated psychiatric syndromes, which are currently 
considered of research interest and potential clinical relevance, 
would be scientifically neglected or “orphaned.” The reality that 
CSF is often difficult to obtain in these patients, and multiple 
assay methods to evaluate serum are rarely available outside 
specialist centers, compounds this issue.
Furthermore, a negative CSF result should not automatically 
render NSAb seropositivity irrelevant. First, some NSAbs, such 
as LGI1, are detected less frequently in CSF, in this case in half 
or less of LGI1 AE cases (15). Second, if NSAbs are pathogenic 
in some of the isolated psychiatric presentations in which they 
are detected, it is likely that they occur at lower titers than in 
fulminant AE. Furthermore, the brain parenchyma can act as an 
“immunoprecipitator” of NMDAR antibodies (16), so unless the 
parenchyma is “saturated” by an extremely high concentration of 
antibody, it is plausible to expect that NSAbs may not be found in 
the CSF while still directly disrupting brain function.
We propose that these challenges for the field can be addressed 
by use of a syndrome-level taxonomy. Patients with isolated 
psychiatric symptoms and detectable NSAb can be characterized 
as “synaptic and neuronal autoantibody-associated psychiatric 
syndromes,” abbreviated to “SNAps” (Figure 1A). SNAps delib-
erately have less stringent criteria for onset time, antibody class, 
and assay criteria. This enables a broad category, agnostic to the 
precise pathogenic role of the NSAb. In real time, additional 
serum antibody tests, identification of CSF antibody, or further 
investigations (e.g., MRI, EEG) may reveal abnormalities that 
meet the diagnostic criteria for AE, and presuming that new 
symptom domains do not evolve, these patients can then be 
characterized as having SNAps-AE (see Table 1). Patients with 
clear features of AE would continue to be classified as such. We 
suggest that this model, in which an NSAb-associated isolated 
clinical syndrome and AE partially overlap, can be extended to 
other syndromes such as epilepsy (17) and cognitive impairment 
FigUre 1 | (a) Patients with isolated psychiatric symptoms and a detectable 
neural surface antibody can be characterized as having a “synaptic and 
neuronal autoantibody-associated psychiatric syndrome,” abbreviated to 
“SNAps.” This distinguishes these patients from the majority of patients with 
autoimmune encephalitis (AE), which is normally a multi-symptom disorder 
with specific associated clinical and paraclinical features: diagnostic criteria 
for AE have been outlined in a recent position paper (14). Some patients with 
isolated psychiatric symptoms will also meet criteria for AE—these patients 
are here referred to as SNAps-AE and are clinically atypical for AE by virtue of 
their monosymptomatic presentation. (B) The distinction between an isolated 
symptomatic presentation and a polysymptomatic AE presentation can 
usefully be extended to non-psychiatric presentations. This scheme 
recognizes that there will be areas of overlap where a monosymptomatic 
presentation meets paraclinical criteria for AE e.g. imaging, 
electroencephalogram, or cerebrospinal fluid parameters. Here ‘md’ stands 
for movement disorder, ‘cog’ is cognitive disorder, and ‘epi’ is epilepsy.
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(18) (see Figure  1B). Table  2 demonstrates that many of the 
signs and symptoms of AE are in fact seen (often to an attenuated 
degree) in patients with so called “isolated” psychosis, suggesting 
that the overlap between these conditions may be even greater 
still. The nascence of the field would suggest this system to be 
clinically pragmatic and also heuristic, promoting the delinea-
tion of biologically defined disease sub-classes and, equally as 
important, the signals that imply lack of disease relevance.
are nsabs in snaps direCtLy 
patHogeniC, indireCt MarKers, or 
innoCent Bystanders?
Most NSAbs appear to share a common mechanism of action 
in their ability to cause cross-linking and internalization of 
their target antigen (4). Where the target is a neurotransmit-
ter ion channel receptor, it is likely that the resulting receptor 
hypofunction results in impaired neurotransmitter signaling, 
as demonstrated by abolition of currents on some neurophysi-
ological assays and alterations in synaptic plasticity (31, 32). 
Although not proven, the rationale for this causing the signs 
and symptoms of NSAb-associated disease is compelling and 
the “receptor hypofunction” model resonates well with many 
current theories of psychiatric disorders (33). Importantly, 
pathogenic potential as indexed by effects on receptor internali-
zation and postsynaptic currents in vitro has been demonstrated 
for NMDAR antibodies taken from patients with schizophrenia 
(10, 34) and to a lesser extent bipolar disorder (35), demon-
strating that pathogenicity is not restricted to NSAbs found in 
encephalitic presentations.
Synaptic dysfunction affecting glutamatergic neurotrans-
mission has been proposed as a mechanism in schizophrenia, 
bipolar disorder, and major depression (36–38). We consider 
that antibody-mediated glutamatergic synaptic dysfunction, 
if relevant to psychiatric symptomatology, is likely to have 
relevance that cuts across traditional diagnostic boundaries. 
For example, the psychiatric phase of NMDAR-AE can include 
a diverse range of symptoms including affective and anxiety 
in addition to psychosis (39) and prevalence estimates detect 
NMDAR antibodies across traditional diagnostic boundaries 
(40). If NMDAR antibodies are pathogenic outside of encepha-
litis, then we could expect the psychiatric manifestations to 
have similar clinical heterogeneity. Nonetheless, only further 
clinicopathological correlation of SNAps will help determine an 
accurate picture. Such study may help validate or suggest new 
directions for receptor-based models of idiopathic psychiatric 
syndromes.
Alternatively, NSAbs in SNAps may not be directly pathogenic 
but still are part of the primary disease process, for example, as 
part of a broader immune and/or inflammatory syndrome which 
may be IT responsive. A randomized controlled trial could 
interrogate this, but to be robust would need to be designed and 
powered to test multiple forms of IT and detect partial responses.
Another possible role for NSAbs in SNAps is as a prognostic 
marker, thereby allowing disease stratification. This may include 
likely response to antipsychotic medication, or illness trajectory. 
Cohort studies would best assess this hypothesis. Suitable popula-
tions might include those at ultra-high risk or in the prodromal 
phase of a psychiatric disorder, in whom such biomarkers are 
already sorely needed.
A final potential role of NSAb is as part of a secondary 
process, following a separate primary disease process. The pres-
ence of NSAbs in disorders such as herpes simplex encephalitis, 
Alzheimer’s disease, Creutzfeldt–Jakob disease, and other demen-
tia types (18, 41–43) strongly suggests that NSAb production 
sometimes occurs following neuronal destruction. Nonetheless, 
“secondary” antibodies can still have pathogenic potential: in 
dementia, NSAbs may confer a higher risk of psychosis (43), and 
in patients who have had herpes simplex encephalitis, NSAbs 
associate with greater cognitive impairment (44).
It is plausible that NSAbs associated with psychiatric disease 
fall into this “phenotype-modifying” category. For example, 
NMDAR antibodies may be found in psychosis because the 
primary pathology has rendered NMDARs immunogenic. Other 
“immunizing” conditions could include late pregnancy and par-
turition, around which time numerous immunological rebound 
changes are understood to occur (45). Indeed NSAbs have been 
taBLe 1 | Comparison of position statement on diagnosis of autoimmune encephalitis (ae) and proposed snaps concept.
position paper ae diagnosis (14) proposed snaps concept
definite anti-nMda receptor encephalitis synaptic and neuronal autoantibody-
associated psychiatric syndrome 
(snaps)-ae
snaps
reasonable exclusion of other disorders
Clinical features Onset <3 months of 1 of 6 symptom groups
 1. Abnormal (psychiatric) behavior or cognitive dysfunction
 2. Speech dysfunction
 3. Seizures
 4. Movement disorder, dyskinesias, or rigidity/abnormal 
postures
 5. Decreased conscious level
 6. Autonomic dysfunction or central hypoventilation
Onset <3 months of 1 symptom group
 1. Abnormal (psychiatric) behavior
Any onset of 1 
symptom group
 1. Abnormal 
(psychiatric) behavior
Cerebrospinal fluid (CSF) With or without With or without Absent
Pleocytosis OR oligoclonal bands Pleocytosis OR oligoclonal bands
Electroencephalogram (EEG) With or without With or without Absent
Focal/diffuse slow or disorganized activity OR epileptic 
activity OR extreme delta brush
Focal/diffuse slow or disorganized activity OR 
epileptic activity OR extreme delta brush
Magnetic Resonance Imaging 
(MRI)
With or without With or without Absent
Changes suggestive of encephalitis Changes suggestive of encephalitis
Autoantibody
•	 Class IgG IgG IgG OR IgM OR IgA
•	 Target NMDAR GluN1 NMDAR GluN1 NMDAR GluN1
NMDAR GluN1 + 2
GABAAR
GABABR
AMPAR
LGI1
Caspr2
OR unknown target
Sample required
•	 Cell-based assay (CBA) only CSF ± serum CSF ± serum Serum
•	 CBA and confirmatory test (live 
neurons or immunohistochemistry)
Serum Serum ± Absent
NMDAR antibodies are the most frequently identified neural surface antibody in isolated psychiatric syndromes; therefore, NMDAR-AE offers the most useful paradigm. It is possible 
to make a diagnosis of NMDAR-AE if an isolated psychiatric syndrome of subacute onset is associated with CSF NMDAR (NR1) antibody or in serum if a CBA result is confirmed by 
testing on neuronal cultures or immunohistochemistry.
A case would be characterized as SNAps if there was a psychiatric syndrome of any speed of onset with serum antibody of any class against a central nervous system neuronal 
surface target detected on CBA. We argue that cases of NMDAR-AE with only a psychiatric syndrome share aspects of both and could be considered “SNAps-AE.” This reflects the 
isolated clinical syndrome atypical of AE, but paraclinical features typical of AE.
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detected in the serum of postpartum psychosis cases (13). These 
women responded to usual psychiatric care and clinically did not 
present as having AE, but even in these situations, the value of IT 
remains to be decided by rigorous trials.
The autoimmune encephalitides have largely been described 
in association with Abs of the IgG isotype, and typically only 
IgG is screened for clinically. While the majority of autoim-
mune disorders are indeed IgG-mediated, numerous instances 
of IgA- and IgM-mediated diseases exist outside of the CNS, 
such as IgA pemphigus and autoimmune hemolytic anemia. 
IgA and IgM NSAbs have been consistently reported in 
psychiatric disorders (9, 46, 47). Importantly, there is in vitro 
evidence of their pathogenicity (18, 34, 35), and IgA and IgM 
seropositivity does appear to associate with clinical phenotype 
in some non-encephalitis conditions (18). We suggest that it is 
premature to dismiss a priori non-IgG NSAbs as irrelevant to 
the disease. For the purposes of our categorical model, IgA or 
IgM seropositivity is included in the definition of SNAps, but 
not of SNAps-AE, implying possible, but not definite, causal 
relevance.
Animal models could potentially demonstrate the patho-
genicity of NSAbs in SNAps, but animal models of AE have 
been slow to develop and often recapitulate a limited facet 
of a complex phenotype (48, 49). The abnormal movements, 
spontaneous seizures, autonomic instability, or psychosis-like 
behaviors associated with AE are notably absent. Nonetheless, 
the animal model of NMDAR encephalitis of Planaguma and 
colleagues (48) appears to be an unintended but plausible model 
taBLe 2 | Clinical overlap between symptoms and signs of autoimmune encephalitis (ae) and psychotic disorders.
Clinical symptom/sign in which ae syndrome? observations in psychotic disorders
Seizures Observed in AE associated with most NSAbs Epilepsy overrepresented in patients with schizophrenia (odds ratio 11.1) (19)
Cognitive dysfunction Observed in AE associated with most NSAbs Observed in schizophrenia across a range of domains. Associated with poor 
function and clinical outcome (20)
Movement disorders Observed in AE associated with most NSAbs 9% of antipsychotic-naive patients with schizophrenia have spontaneous 
dyskinesias; 17% have spontaneous parkinsonism (21)
Catatonia Most marked in NMDAR-AE but observed in cases 
of AE associated with VGKC complex antibodies and 
GABAAR antibodies
Prevalence in psychiatric patients ranges from 7.6% to 38%. 10–15% of 
patients with catatonia have a schizophrenia diagnosis (22)
Language disorders Most marked in NMDAR and AMPAR AE. Catatonic 
speech signs such as echolalia and palilalia are also 
common
“Formal thought disorder” is a cardinal feature of psychotic disorders and 
manifests in disordered speech, sometimes called “schizaphasia”—in some 
cases not distinguishable from neurological dysphasia (23)
Autonomic dysfunction Observed in AE associated with most NSAbs Ambulatory patients with schizophrenia have mean reduced body temperature 
of 0.2°C (24). Meta-analytical evidence of reduced heart rate variability in 
psychotic disorders (25)
Hyponatremia Observed in cases of AE associated with VGKC 
complex antibodies, particularly LGI1
Occurs in 6% of chronic psychiatric patients (26); polydipsia present in 
3–17% of psychiatric patients (27); 40% of psychotic patients admitted with 
unexplained hyponatremia are not taking antipsychotic medication (28)
Antipsychotic sensitivity 
including rhabdomyolysis
Observed in NMDAR-AE Neuroleptic malignant syndrome (rigidity, catatonia, confusion, hyperthermia 
and rhabdomyolysis) occurs in up to 0.07–2.2% of patients taking 
antipsychotics (29). Rhabdomyolysis can occur with water intoxication and 
hyponatremia
Sleep dysfunction Observed in AE associated with most NSAbs. 
Particularly marked in NMDAR-AE- and  
IGLON-5-associated encephalopathy
Reported in 30–80% of patients with schizophrenia. Consistent findings include 
increased sleep onset latency, diminished slow wave sleep time, and decreased 
REM latency (30)
5
Al-Diwani et al. SNAps: Controversies and Hypotheses
Frontiers in Psychiatry | www.frontiersin.org February 2017 | Volume 8 | Article 13
of NMDAR antibody-mediated depressive behavior. Future work 
on an animal model of SNAps should attempt to integrate passive 
NSAb transfer experiments with established psychiatric animal 
endophenotypes. For example, in a potential model of psychosis, 
multiple behavioral and neurophysiological indices such as latent 
inhibition and mismatch negativity could be assessed alongside 
the neuronal effects of antibodies (50).
Ultimately, in vivo human studies of SNAps will be necessary 
to elucidate whether NSAbs differentially impact brain function 
in psychiatric presentations. Functional MRI and magnetic 
resonance spectroscopy offer equivalent promise in restricted 
psychiatric presentations as for more fulminant neurological 
presentations (51, 52). With the development of PET and SPECT 
ligands for in vivo measurement of microglial activation (53, 54) 
and the function of individual receptor types [e.g., NMDAR (55) 
and GABAR (56)] or neurotransmitter synthesis capacity (57), it 
is likely that this methodology can offer insights into the molecu-
lar pathology of SNAps. Correlation of clinical improvement 
with improvement in disease-relevant biomarkers (for example, 
a perturbed glutamate MRS signal or ketamine-like functional 
dysconnectivity) following antibody removal would strengthen 
an argument for in vivo pathogenicity in SNAps. Conversely, an 
absence of differences from seronegative patients with psychiatric 
disorders on such neuroimaging measures would make it less 
likely that NSAbs directly affect brain function.
does the Blood–Brain Barrier  
(BBB) Have a role?
As a number of studies have reported similar seroprevalences 
in NSAbs in individuals with multiple psychiatric diseases and 
healthy controls, some authors have postulated that disruption of 
the BBB must be present for NSAbs to be pathogenic (9).
Beyond defining what “BBB disruption” actually means 
(disruption of tight junctions, permeability to macromolecules, 
and hyper- or hypofunction of transporter mechanisms have 
all been suggested), it is difficult to demonstrate in vivo. Serum 
markers, such as calcium-binding glial protein S100B, appear 
to correlate well with BBB disruption in some conditions but 
not others (58). Until recently, neuroimaging approaches were 
only able to reveal gross BBB disruption, but newer dynamic 
contrast-based techniques may allow for the identification of 
more subtle impairments (59). The need for a simultaneous 
lumbar puncture and blood test makes the gold standard test, 
CSF/serum albumin ratio (Qalb), difficult to obtain in psychi-
atric practice.
Proxy markers of BBB disruption may have to suffice. Work 
by Ehrenreich and colleagues have demonstrated that only in the 
presence of a history of birth complications and “neurotrauma” 
does NMDAR seropositivity in schizophrenia predispose to more 
severe neurological symptoms (10). Additionally, drawing on ani-
mal work demonstrating that ApoE4 carriers have a chronically 
FigUre 2 | experimentally testable hypotheses relating to the pathogenicity of neural surface antibodies (nsabs) in synaptic and neuronal 
autoantibody-associated psychiatric syndromes (snaps).
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“leaky” BBB, Hammer and colleagues demonstrated that patients 
with schizoaffective disorder show a higher than expected co-
occurrence of NMDAR Abs and ApoE4 carrier status compared 
to patients with other psychiatric diagnoses and healthy controls, 
suggesting that in seropositive individuals, a leaky BBB confers 
susceptibility toward a schizoaffective phenotype (60).
We suggest that Qalb or dynamic contrast-enhanced imag-
ing is used in prospective studies of SNAps where possible, to 
explore the potentially disease-mediating role of the BBB (see 
Figure 2).
HoW Can We integrate tHese 
Findings into psyCHiatriC 
praCtiCe?
Who should Be tested for nsabs, and 
Which tests should Be requested?
The need to identify cases of possible AE at an early stage in 
psychiatric practice is not controversial. However, the breadth of 
screening is a matter of active discussion. Many cases of definite 
AE will, even early in their course, have clinical features that 
prompt presentation to medical services where the likelihood 
of neurological evaluation including NSAb testing is higher. 
However, in diseases such as NMDAR-AE, psychiatric symptoms 
may predominate for the first weeks (or sometimes months) of 
the illness (61) and occasionally may not progress any further 
(62) (this is a situation that we have referred to as SNAps-AE in 
Figure 1 and Table 1).
It is likely that many of these cases satisfy current criteria for 
“possible AE” as per Graus et al. (14), and some that eventually go 
on to receive a diagnosis of “probable” or “definite” NMDAR-AE 
are initially diagnosed as having a primary psychiatric disorder 
and are at risk of suboptimal management.
Although prior to the discovery of AE it is likely that some 
cases spontaneously remitted (63–65), there is clear, albeit neces-
sarily observational, evidence that short- and long-term medical 
and neuropsychiatric prognosis is linked to early clinical identi-
fication of AE and timely instigation of IT, frequently before the 
antibody status is known (66). Therefore, we suggest that cases of 
FEP or severe mood disturbance such as mania or severe depres-
sion, here grouped as “severe mental illness” (SMI), with subacute 
onset (less than 3 months), should be regarded as “yellow flag” 
cases, at risk of AE, and undergo testing for a serum NSAb panel. 
Cases with both yellow and additional “red flag” clinical features 
suggestive of AE should be more obvious to differentiate clini-
cally, and likelihood of detection of relevant NSAb detection is 
high (see Figures 3 and 4).
For cases of SMI with (a) an onset of longer than 3 months, 
(b) in relapse, or (c) in a chronic phase—referred to as “gray 
flag” cases—there is growing evidence to suggest that many 
of these cases will have NSAbs without differentiating clinical 
features (67), and that many of these may stand to benefit from 
IT (68). However, blanket screening of such cases outside of 
clearly defined research programs risks generating uncertainty 
insofar as antibody-positive patients may be identified before 
a clear and evidence-based understanding of their optimal 
management is known. Therefore, we would strongly advocate 
screening in these cases to be based within research settings (see 
Figure 5).
How should psychiatrists Understand  
a positive test?
Local experience has found that NSAb screening in subacute onset 
first-episode presentations and more long-standing instances of 
serious mental illness (SMI) helps to identify cases of AE that will 
benefit from IT. However, as with any screening test, there will be 
positive results of less clear clinical significance. For example, in 
FigUre 3 | relationship between severe mental illness (sMi) and the neural surface antibody (nsab) seropositivity iceberg: psychiatrists will see 
both autoimmune encephalitis (ae), and synaptic and neuronal autoantibody-associated psychiatric syndromes (snaps), and overlap areas. In 
practice, this means that all first-episode SMI with a subacute onset should be regarded as a yellow flag for AE and should be screened for relevant NSAbs (see 
Figure 4). If these cases have red flag clinical features, then there should be a low threshold for further investigations and liaison with neurology colleagues (see 
Figure 5). Screening cases of SMI with a longer onset or treatment resistance will yield cases with NSAbs; however, the management of these cases is less certain. 
There is an imperative for further well-designed research studies to characterize the biology and immunotherapy responsiveness of these cases.
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those in whom illness does not clearly satisfy criteria for AE, or is 
spontaneously remitting, or is responding well to psychological 
or psychotropic approaches.
We would advocate that, where possible, cases of SNAps are 
assessed in detail in a specialist joint neurology–psychiatry clinic. 
Such services will often be based at research-associated regional 
neuroscience centers with access to neuropsychology, brain 
imaging (MRI and increasingly PET), and lumbar puncture/CSF 
analysis expertise.
We suggest taking a pragmatic approach incorporating avail-
able resources and tolerability to investigation. We hope this 
could prompt clinicians to consider how psychiatric services 
could incorporate the developments from this rapidly growing 
field. Specialist clinical work closely allied with multidisciplinary 
research units will be central in identifying biomarkers of future 
classificatory and clinical relevance (summarized in Figure 5).
Who should receive nsab-Modifying it?
While the evidence for short- and long-term benefits for IT in 
AE is clear, clinicians managing SNAps have greater equipoise. If 
NSAbs in these cases are indeed pathogenic, care must be taken 
to minimize the duration of untreated autoimmune CNS disease. 
However, the medical risks of IT are not trivial, and pathogenic-
ity of NSAbs in SNAps has not been demonstrated definitively. 
Although open-label data (68) and many case reports (7, 69–71) 
show promising effects of IT in cases of psychosis, these results 
do not exclude placebo response or regression to the mean. 
Duration of adequate treatment and optimal treatment of 
relapses is not clear.
FigUre 4 | initial serum neural surface antibody panel recommended 
in subacute onset first-episode severe mental illness, at risk for 
autoimmune encephalitis, and to consider in cases with longer onset.
FigUre 5 | suggested algorithm for neural surface antibody (nsab) testing and further management in the context of severe mental illness (sMi).
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In our experience, there is another potential hazard that can 
arise when discussing the possible relevance of NSAbs with 
seropositive patients: in some cases, the patient and/or their carer 
may develop unhelpful biomedically reductionist illness beliefs 
(e.g., “I don’t have a mental health problem. I have encephalitis. 
That’s what the antibody test shows.”) which prevent engagement 
in vital psychosocial interventions.
Given such equipoise, there is a clear and pressing need for 
adequately powered and robustly designed randomized con-
trolled trials to determine whether SNAps cases benefit from IT.
What other treatments should  
Be Considered?
Identifying SNAps may also allow better targeting of existing treat-
ments. For example, sensitivity to antipsychotic medication and 
propensity to neuroleptic malignant syndrome-type complica-
tions occur relatively commonly in AE and overlap areas (72, 73). 
In some cases of AE, patients experience treatment-resistant 
psychiatric symptoms despite IT, and several reports note the 
efficacy of electroconvulsive therapy (ECT) in this situation (74). 
The mechanism of this, in the context of an identified molecular 
pathology, is intriguing. From a clinical perspective, it implies 
that ECT may be a specific intervention worth considering early 
in SNAps.
Also intriguing is early evidence of SNAps acting as a paradigm 
for intervention with rational molecular-based psychopharma-
cology. For example, Heresco-Levy and colleagues found that 
the NMDAR co-agonist d-serine could improve psychopathol-
ogy in a case of chronic treatment-resistant schizophrenia with 
NMDAR antibodies (75). This approach could be widened to 
other antibodies implicated in SNAps.
ConCLUsion
The description of AE syndromes caused by NSAbs has pro-
foundly impacted neurological practice and has invigorated 
neuroimmunology as a basic and clinical science. The extent to 
which the paradigm—of autoantibodies affecting brain function 
and behavior—has relevance for clinical psychiatry is a matter of 
considerable debate.
We have introduced the concept of SNAps as an attempt to 
clarify some of the issues in this sometimes confusing field. By 
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making the distinction between AE and isolated psychiatric 
presentations associated with NSAbs, we hope to encourage 
the latter as an important focus of research in its own right. It 
is now generally accepted that many psychiatric disorders may 
be comprised of subgroups that are phenotypically similar but 
heterogeneous in their etiologies. We believe that the category 
of SNAps offers a well-defined candidate for one such subgroup, 
and we have offered suggestions as to how this hypothesis may 
be tested.
Research on SNAps will of course be informed by the AE lit-
erature to date, particularly in terms of pathogenic mechanisms. 
In this article, we have outlined the increasingly compelling 
evidence that NSAbs may have pathogenic potential in SNAps: 
we are clear however that considerable further work needs to 
be done in this area before generalized statements can be made 
about pathogenicity. Further, we would suggest that much of this 
work needs to be led by psychiatrists. The nuances of psychiatric 
signs and symptoms are often ignored within the neurological 
literature, and while this remains the case, a “psychiatric pheno-
type” associated with NSAbs will remain elusive.
The possibility that the SNAps concept may delineate a 
subgroup of psychiatric patients with a differential treatment 
response (including a potential IT response) remains an excit-
ing focus of future research. In an area of medicine where novel 
therapies are relatively rare and where immune therapies are 
increasingly under the spotlight, SNAps represent a focus for 
therapeutic studies that could be potentially transformative for 
the field.
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